<?xml version="1.0" encoding="UTF-8"?>
<p id="para0089">This group also categorized as mild to moderate disease but patients have risk factors such as the age of over 60 years and patients with underlying diseases (ex. liver disease, kidney disease, heart disease, diabetes, chronic obstructive pulmonary disease, hypertension, etc.) In this group, lopinavir/ritonavir plus chloroquine or hydroxychloroquine would be considered. Also according to the therapeutic protocol in each country, each of these drugs may be administered as monotherapy. The recommended duration of therapy in this group is 5 to 7 days.
 <xref rid="bib0082" ref-type="bibr">
  <sup>82</sup>
 </xref>
</p>
